Intervention Review

Rivastigmine for Alzheimer's disease

  1. Jacqueline Birks1,*,
  2. John Grimley Evans2,
  3. Vasso Iakovidou3,
  4. Magda Tsolaki4

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 15 APR 2009

Assessed as up-to-date: 8 SEP 2008

DOI: 10.1002/14651858.CD001191.pub2

How to Cite

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.pub2.

Author Information

  1. 1

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  2. 2

    University of Oxford, Division of Clinical Geratology, Nuffield Department of Clinical Medicine, Oxford, UK

  3. 3

    Thessaloniki, Makedonia, Greece

  4. 4

    Aristotle University of Thessaloniki, 3rd Neurology Department, Thessaloniki, Macedonia, Greece

*Jacqueline Birks, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, OX2 6UD, UK. jacqueline.birks@csm.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 15 APR 2009

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kenneth Alper, Maarten E.A. Reith, Henry Sershen, Ibogaine and the inhibition of acetylcholinesterase, Journal of Ethnopharmacology, 2012, 139, 3, 879

    CrossRef

  2. 2
    Adrienne M. Gilligan, Daniel C. Malone, Terri L. Warholak, Edward P. Armstrong, Racial and Ethnic Disparities in Alzheimer's Disease Pharmacotherapy Exposure: An Analysis Across Four State Medicaid Populations, The American Journal of Geriatric Pharmacotherapy, 2012, 10, 5, 303

    CrossRef

  3. 3
    Jeannine Skinner, Janessa O. Carvalho, Guy G. Potter, April Thames, Elizabeth Zelinski, Paul K. Crane, Laura E. Gibbons, The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI, Brain Imaging and Behavior, 2012, 6, 4, 489

    CrossRef

  4. 4
    Daniel Rodríguez, Francesc Formiga, Isabel Fort, María José Robles, Elena Barranco, Dolors Cubí, Tratamiento farmacológico de la demencia: cuándo, cómo y hasta cuándo. Recomendaciones del Grupo de Trabajo de Demencias de la Sociedad Catalana de Geriatría y Gerontología, Revista Española de Geriatría y Gerontología, 2012, 47, 5, 228

    CrossRef

  5. 5
    Albert Diefenbacher, Ronald Burian, Christian Klesse, Martin Härter, Psychische Erkrankungen, 2012,

    CrossRef

  6. 6
    Clive Ballard, Serge Gauthier, Anne Corbett, Carol Brayne, Dag Aarsland, Emma Jones, Alzheimer's disease, The Lancet, 2011, 377, 9770, 1019

    CrossRef

  7. 7
    Harald Hampel, Gordon Wilcock, Sandrine Andrieu, Paul Aisen, Kaj Blennow, K. Broich, Maria Carrillo, Nick C. Fox, Giovanni B. Frisoni, Maria Isaac, Simon Lovestone, Agneta Nordberg, David Prvulovic, Christina Sampaio, Philip Scheltens, Michael Weiner, Bengt Winblad, Nicola Coley, Bruno Vellas, Biomarkers for Alzheimer's disease therapeutic trials, Progress in Neurobiology, 2011, 95, 4, 579

    CrossRef

  8. 8
    Gary Small, Roger Bullock, Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease, Alzheimer's & Dementia, 2011, 7, 2, 177

    CrossRef

  9. 9
    Milap A. Nowrangi, Vani Rao, Constantine G. Lyketsos, Epidemiology, Assessment, and Treatment of Dementia, Psychiatric Clinics of North America, 2011, 34, 2, 275

    CrossRef

  10. 10
    R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro, A.L. Gobartt Vázquez, Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease, Neurología (English Edition), 2011, 26, 5, 262

    CrossRef

  11. 11
    Catarina Freitas, Helena Mondragón-Llorca, Alvaro Pascual-Leone, Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future, Experimental Gerontology, 2011,

    CrossRef

  12. 12
    M. Llanero Luque, J.M. Ruiz Sánchez de León, P. Medrano Izquierdo, C. Fernández García, Tratamiento de la enfermedad de Alzheimer, Medicine - Programa de Formación Médica Continuada Acreditado, 2011, 10, 76, 5138

    CrossRef

  13. 13
    Reginald P. Sequeira, A worldwide yearly survey of new data in adverse drug reactions, 2011,

    CrossRef

  14. 14
    Jason T. Olin, Vinod Bhatnagar, Patricio Reyes, Barbara Koumaras, Xiangyi Meng, Stephen Brannan, Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32), International Journal of Geriatric Psychiatry, 2010, 25, 4
  15. You have free access to this content15
    Cochrane reviews – in their own words, Journal of Evidence-Based Medicine, 2009, 2, 4
  16. You have free access to this content16
    Mike Clarke, Li Youping, Editorial for issue 4 of 2009, Journal of Evidence Based Medicine, Journal of Evidence-Based Medicine, 2009, 2, 4
  17. 17
    Tom C Russ, Joanne Morling, Cholinesterase inhibitors for mild cognitive impairment, The Cochrane Library,
  18. 18
    Tom C Russ, Joanne R Morling, Cholinesterase inhibitors for mild cognitive impairment, The Cochrane Library,